Monopar Therapeutics - FORM 10-K - EX-32.1 - CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANE - March 26, 2018

Attached files

file filename
10-K - MONOPAR THERAPEUTICS INC. - Monopar Therapeuticsmnpr_form10k.htm
EX-31.2 - CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF - Monopar Therapeuticsexhibit_31-2.htm
EX-31.1 - CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF - Monopar Therapeuticsexhibit_31-1.htm
EX-14 - CODE OF BUSINESS CONDUCT AND ETHICS - Monopar Therapeuticsexhibit_14.htm
EX-11 - STATEMENT RE: COMPUTATION OF PER SHARE EARNINGS - Monopar Therapeuticsexhibit_11.htm
EX-10.16 - CANCER RESEARCH UK LETTER DATED MARCH 21, 2018 - Monopar Therapeuticsexhibit_10-16.htm
EX-10.15 - TSUCHIMOTO EMPLOYMENT AGREEMENT AMENDMENT ONE - Monopar Therapeuticsexhibit_10-15.htm
EX-10.14 - PRX CONSULTING AGREEMENT 2018 - Monopar Therapeuticsexhibit_10-14.htm
EX-10.13 - ANDERSON EMPLOYMENT AGREEMENT - Monopar Therapeuticsexhibit_10-13.htm
EX-10.12 - PRX CONSULTING AGREEMENT 2017 - Monopar Therapeuticsexhibit_10-12.htm
EX-10.11 - MAZAR EMPLOYMENT AGREEMENT - Monopar Therapeuticsexhibit_10-11.htm
EX-10.10 - MAZAR CONSULTING AGREEMENT - Monopar Therapeuticsexhibit_10-10.htm
EX-10.9 - TSUCHIMOTO EMPLOYMENT AGREEMENT - Monopar Therapeuticsexhibit_10-9.htm
EX-10.8 - TSUCHIMOTO CONSULTING AGREEMENT - Monopar Therapeuticsexhibit_10-8.htm
EX-10.7 - ROBINSON EMPLOYMENT AGREEMENT AMENDED AND RESTATED - Monopar Therapeuticsexhibit_10-7.htm
EX-10.6 - ROBINSON EMPLOYMENT AGREEMENT - Monopar Therapeuticsexhibit_10-6.htm
EX-10.5 - MONOPAR THERAPEUTICS INC. 2016 STOCK INCENTIVE PLAN - Monopar Therapeuticsexhibit_10-5.htm
EX-10.4 - TACTICGEM CONTRIBUTION AGREEMENT - Monopar Therapeuticsexhibit_10-4.htm
EX-10.3 - ONXEO OPTION AND LICENSE AGREEMENT - Monopar Therapeuticsexhibit_10-3.htm
EX-10.2 - XOMA LICENSE AGREEMENT - Monopar Therapeuticsexhibit_10-2.htm
EX-10.1 - CANCER RESEARCH UK CTOA - Monopar Therapeuticsexhibit_10-1.htm
EX-3.2 - AMENDED AND RESTATE BYLAWS - Monopar Therapeuticsexhibit_3-2.htm
EX-3.1 - SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION - Monopar Therapeuticsexhibit_3-1.htm
 
 
Exhibit 32.1
 
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Annual Report on Form 10-K of Monopar Therapeutics Inc. (the Company) for the year ended December 31, 2017, as filed with the Securities and Exchange Commission on the date hereof (the Report), we, Chandler D. Robinson, and Kim R. Tsuchimoto, hereby certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:
(1)
the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
 
 
/s/ CHANDLER D. ROBINSON
 
Chandler D. Robinson
 
Chief Executive Officer
 
March 26, 2018
 
 
 
/s/ KIM R. TSUCHIMOTO
 
Kim R. Tsuchimoto
 
Chief Executive Officer
 
March 26, 2018
 
 
 
  
This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Monopar Therapeutics Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.
 
 
 

Monopar Therapeutics Reports

Also read